长链非编码RNA在血液肿瘤中的研究进展  

Re se arch Progre ss of Long Non-Coding RNA in He matological Tumors——Review

作　　者：李凤 杨斐斐 徐燕丽[1] LI Feng;YANG Fei-Fei;XU Yan-Li(Department of Hematology,Nanjing First Hospital,Nanjing Medical University,Nanjing 210000,Jiangsu Province,China)

机构地区：[1]南京医科大学附属南京医院,南京市第一医院血液内科,江苏南京210000

出　　处：《中国实验血液学杂志》2023年第1期306-310,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金资助项目(82000160);南京市卫生科技发展项目(YKK21138)。

摘　　要：长链非编码RNA(lncRNA)作为肿瘤发病机制研究领域的热点,其在血液系统恶性肿瘤中的重要性正逐渐被阐明。lncRNA不仅影响细胞增殖、分化、多能性和凋亡等多种生物学过程,调控血液肿瘤发生和进展,而且lncRNA异常表达和突变与耐药和预后密切相关,可作为血液肿瘤的新型生物标志物和潜在治疗靶点。本文将重点介绍lncRNA在血液肿瘤中的最新进展,为血液病的临床诊断、预后评估和靶向药物的研发提供新思路。Long non-coding RNA(lncRNA) is a hot topic in the field of researching tumor pathogenesis, and the importance in hematologic malignancies has been gradually being elucidated. LncRNA not only regulates hematological tumorigenesis and progression through affecting various biological processes such as cell proliferation, differentiation, pluripotency and apoptosis;moreover, abnormal expression and mutation of lncRNA are closely related to drug resistance and prognosis. Thus lncRNA can be used as novel biomarker and potential therapeutic target for hematological tumors. In this review, we will focus on the latest progress of lncRNA in hematological tumors to provide new ideas for the clinical diagnosis, prognostic evaluation together with research and development of target drugs for hematologic malignancies.

关 键 词：长链非编码RNA 血液系统恶性肿瘤 生物标志物 治疗靶点 

分 类 号：R733[医药卫生—肿瘤]